Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression

Dennis Mauricio, Stefania Bellone, Levent Mutlu, Blair McNamara, Diego Manavella, Cem Demirkiran, Miguel Skyler Z. Verzosa, Natália Buza, Pei Hui, Tobias M.P. Hartwich, Justin Harold, Yang Yang‐Hartwich, Margherita Zipponi, Gary Altwerger, Elena Ratner, Gloria S. Huang, Mitchell Clark, Vaagn Andikyan, Masoud Azodi, Peter E. Schwartz, Alessandro D. Santin